South Korea: SunBio raises around US$4.8m through issuance of new shares in Korea

SunBio, a biotech company developing biosimilars, biopharmaceuticals, and medical devices based on its proprietary technologies of pegylation, has issued new shares through a general Initial Public Offering for listing on the KOSDAQ stock exchange. The company placed 616,000 shares at a price of WON11,000 per share to raise a total of WON6.778bn (US$4.81m). SunBio’s biosimilar product, PEG-filgrastim, has…

You must be a HMI Subscriber to view this content.

Subscribe Now »